Intimation of Resignation of Chief Financial officer under regulation 30 of SEBI(LODR) Regulation 2015
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mr. Altaf Hussain (DIN: 10351528) has resigned from his dual roles as Managing Director and Chief Financial Officer of Welcure Drugs & Pharmaceuticals Ltd, effective from the close of business hours on 5th May 2025. He cited personal reasons and other professional commitments as the reason for stepping down, and confirmed there are no other material reasons behind the exit. The Board has recorded its appreciation for his contributions during his tenure. No replacement for either role has been announced in this filing, and the intimation has been signed by Suraj Chagan Solanki, a Director on the board.
Losing both the MD and CFO at the same time is a significant leadership vacuum for a small-cap pharmaceutical company and may concern shareholders about continuity in financial reporting and strategic execution. Investors should watch for a timely appointment of a new CFO and MD, as prolonged gaps could weigh on the stock price and signal governance weakness.